All In Biotech

Drug Trial Radar · NCT06383390

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 10,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

10,000

Planned (sponsor's estimate)

Start

Apr 30, 2024

Primary completion

Feb 2029

Study completion Feb 2029

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Apr 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.

Conditions

  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • Chronic Kidney Disease (CKD)

Interventions

  • RetatrutideDrug

    Administered SC

  • PlaceboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurrence of Composite EndpointsTime frame: Randomization up to Study Completion (Approximate 248 Weeks)
  2. Time to First Occurrence of Composite Endpoint of End Stage Kidney Disease (ESKD), ≥ 40% Sustained Decline in Estimated Glomerular Filtration Rate (eGFR), CV Death or Renal DeathTime frame: Randomization up to Study Completion (Approximate 248 Weeks)

Locations

742 sites in 27 countries. Site status is shown where the registry gives one.

  • Alabama Kidney Research

    Alabaster, Alabama

  • Central Research Associates

    Birmingham, Alabama

  • Alliance for Multispecialty Research, LLC

    Daphne, Alabama

  • Nephrology Consultants

    Huntsville, Alabama

  • Alliance for Multispecialty Research, LLC

    Mobile, Alabama

  • Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC

    Gilbert, Arizona

  • Sun City Clinical Research

    Glendale, Arizona

  • Arizona Kidney Disease & Hypertension Center (AKDHC) - Thunderbird

    Glendale, Arizona

  • Helios Clinical Research - SAZ-PDV-026

    Paradise Valley, Arizona

  • Banner University Medical Center Phoenix

    Phoenix, Arizona

  • Elite Clinical Studies, LLC

    Phoenix, Arizona

  • Absolute Clinical Research

    Phoenix, Arizona

  • Scottsdale Clinical Trials

    Scottsdale, Arizona

  • Clinical Research Institute of Arizona (CRI) - Sun City West

    Sun City West, Arizona

  • Synexus Clinical Research US, Inc./Orange Grove Family Practice

    Tucson, Arizona

  • Cardiology and Medicine Clinic

    Little Rock, Arkansas

  • Trident Clinical Research Services, Inc.

    Apple Valley, California

  • Invivo - Bakersfield

    Bakersfield, California

  • American Institute of Research

    Beverly Hills, California

  • Hope Clinical Research, Inc.

    Canoga Park, California

  • Valley Clinical Trials, Inc.

    Covina, California

  • North Coast Cardiology

    Encinitas, California

  • Neighborhood Healthcare Institute of Health

    Escondido, California

  • HB Clinical Trials - Fountain Valley

    Fountain Valley, California

  • Care Access - Huntington Beach

    Huntington Beach, California

  • Irvine Clinical Research

    Irvine, California

  • Scripps Whittier Diabetes Institute

    La Jolla, California

  • Long Beach Research Institute

    Long Beach, California

  • Ark Clinical Research

    Long Beach, California

  • North America Research Institute

    Lynwood, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Desert Oasis Healthcare Medical Group

    Palm Springs, California

  • California Liver Research Institute

    Pasadena, California

  • Western University of Health Sciences

    Pomona, California

  • California Kidney Specialists

    San Dimas, California

  • Southern California Clinical Research

    Santa Ana, California

  • Care Access - Santa Clarita

    Santa Clarita, California

  • Encompass Clinical Research

    Spring Valley, California

  • Valiance Clinical Research

    Tarzana, California

  • Care Access - Thousand Oaks

    Thousand Oaks, California

Showing 40 of 742 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.